BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

390 related articles for article (PubMed ID: 16571091)

  • 1. Incidence of postradioiodine immunogenic hyperthyroidism/Graves' disease in relation to a temporary increase in thyrotropin receptor antibodies after radioiodine therapy for autonomous thyroid disease.
    Schmidt M; Gorbauch E; Dietlein M; Faust M; Stützer H; Eschner W; Theissen P; Schicha H
    Thyroid; 2006 Mar; 16(3):281-8. PubMed ID: 16571091
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Thyrotropin receptor antibodies and Graves' disease, a side-effect of 131I treatment in patients with nontoxic goiter.
    Nygaard B; Knudsen JH; Hegedüs L; Scient AV; Hansen JE
    J Clin Endocrinol Metab; 1997 Sep; 82(9):2926-30. PubMed ID: 9284721
    [TBL] [Abstract][Full Text] [Related]  

  • 3. TSH-receptor autoimmunity in Graves' disease after therapy with anti-thyroid drugs, surgery, or radioiodine: a 5-year prospective randomized study.
    Laurberg P; Wallin G; Tallstedt L; Abraham-Nordling M; Lundell G; Tørring O
    Eur J Endocrinol; 2008 Jan; 158(1):69-75. PubMed ID: 18166819
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Outcome of thyroid function in Graves' patients treated with radioiodine: role of thyroid-stimulating and thyrotropin-blocking antibodies and of radioiodine-induced thyroid damage.
    Chiovato L; Fiore E; Vitti P; Rocchi R; Rago T; Dokic D; Latrofa F; Mammoli C; Lippi F; Ceccarelli C; Pinchera A
    J Clin Endocrinol Metab; 1998 Jan; 83(1):40-6. PubMed ID: 9435414
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Human recombinant TSH preceding a therapeutic dose of radioiodine for multinodular goiters has no significant effect in the surge of TSH-receptor and TPO antibodies.
    Rubio IG; Perone BH; Silva MN; Knobel M; Medeiros-Neto G
    Thyroid; 2005 Feb; 15(2):134-9. PubMed ID: 15753672
    [TBL] [Abstract][Full Text] [Related]  

  • 6. TSH-receptor autoantibodies - differentiation of hyperthyroidism between Graves' disease and toxic multinodular goitre.
    Wallaschofski H; Kuwert T; Lohmann T
    Exp Clin Endocrinol Diabetes; 2004 Apr; 112(4):171-4. PubMed ID: 15127319
    [TBL] [Abstract][Full Text] [Related]  

  • 7. The many causes of subclinical hyperthyroidism.
    Charkes ND
    Thyroid; 1996 Oct; 6(5):391-6. PubMed ID: 8936661
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Administration of thyroxine in treated Graves' disease. Effects on the level of antibodies to thyroid-stimulating hormone receptors and on the risk of recurrence of hyperthyroidism.
    Hashizume K; Ichikawa K; Sakurai A; Suzuki S; Takeda T; Kobayashi M; Miyamoto T; Arai M; Nagasawa T
    N Engl J Med; 1991 Apr; 324(14):947-53. PubMed ID: 1900575
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Appearance of thyroid stimulating antibody and Graves' disease after radioiodine therapy for toxic nodular goitre.
    Chiovato L; Santini F; Vitti P; Bendinelli G; Pinchera A
    Clin Endocrinol (Oxf); 1994 Jun; 40(6):803-6. PubMed ID: 8033373
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Appearance of anti TSH-receptor antibodies and clinical Graves' disease after radioiodine therapy for hyperfunctioning thyroid adenoma.
    Regalbuto C; Salamone S; Scollo C; Vigneri R; Pezzino V
    J Endocrinol Invest; 1999 Feb; 22(2):147-50. PubMed ID: 10195384
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Enhanced thyroid iodine metabolism in patients with triiodothyronine-predominant Graves' disease.
    Takamatsu J; Hosoya T; Naito N; Yoshimura H; Kohno Y; Tarutani O; Kuma K; Sakane S; Takeda K; Mozai T
    J Clin Endocrinol Metab; 1988 Jan; 66(1):147-52. PubMed ID: 3335601
    [TBL] [Abstract][Full Text] [Related]  

  • 12. [Incidence of immunogenic hyperthyroidism after radioiodine therapy of focal thyroid gland autonomy. Results of a multicenter study].
    Weiss M; Görges R; Hirsch C; Bader J; Tatsch K; Hahn K
    Med Klin (Munich); 1999 May; 94(5):239-44. PubMed ID: 10408185
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Disseminated thyroid autonomy or Graves' disease: reevaluation by a second generation TSH receptor antibody assay.
    Meller J; Jauho A; Hüfner M; Gratz S; Becker W
    Thyroid; 2000 Dec; 10(12):1073-9. PubMed ID: 11201852
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Incidence of radiation-induced Graves' disease in patients treated with radioiodine for thyroid autonomy before and after introduction of a high-sensitivity TSH receptor antibody assay.
    Dunkelmann S; Wolf R; Koch A; Kittner C; Groth P; Schuemichen C
    Eur J Nucl Med Mol Imaging; 2004 Oct; 31(10):1428-34. PubMed ID: 15221291
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Incidence of radioiodine induced Graves' disease in patients with multinodular toxic goiter.
    Meller J; Siefker U; Hamann A; Hüfner M
    Exp Clin Endocrinol Diabetes; 2006 May; 114(5):235-9. PubMed ID: 16804797
    [TBL] [Abstract][Full Text] [Related]  

  • 16. The tale of radioiodine and Graves' orbitopathy.
    Ponto KA; Zang S; Kahaly GJ
    Thyroid; 2010 Jul; 20(7):785-93. PubMed ID: 20578895
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Pretreatment with betamethasone of patients with Graves' disease given radioiodine therapy: thyroid autoantibody responses and outcome of therapy.
    Gamstedt A; Karlsson A
    J Clin Endocrinol Metab; 1991 Jul; 73(1):125-31. PubMed ID: 2045463
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Sensitive thyrotropin and thyrotropin-receptor antibody determinations one month after discontinuation of antithyroid drug treatment as predictors of relapse in Graves' disease.
    Quadbeck B; Hoermann R; Roggenbuck U; Hahn S; Mann K; Janssen OE;
    Thyroid; 2005 Sep; 15(9):1047-54. PubMed ID: 16187913
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Induction of stimulating thyrotropin receptor antibodies after radioiodine therapy for toxic multinodular goitre and Graves' disease measured with a novel bioassay.
    Hovens GC; Heemstra KA; Buiting AM; Stokkel MP; Karperien M; Ballieux BE; Pereira AM; Romijn JA; Smit JW
    Nucl Med Commun; 2007 Feb; 28(2):123-7. PubMed ID: 17198353
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Late manifestation of subclinical hyperthyroidism after goitrogenesis in an index patient with a N670S TSH receptor germline mutation masquerading as TSH receptor antibody negative Graves' disease.
    Schaarschmidt J; Paschke S; Özerden M; Jäschke H; Huth S; Eszlinger M; Meller J; Paschke R
    Horm Metab Res; 2012 Dec; 44(13):962-5. PubMed ID: 22763653
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 20.